statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United...

Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa

Soligenix Announces Pricing of $4.75 Million Public Offering Soligenix Announces Pricing of $4.75 Million Public Offering PR Newswire PRINCETON, N.J., April 18, 2024 PRINCETON, N.J., April 18, 2024...

Soligenix Announces Pricing of $4.75 Million Public Offering

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection FDA Grants Soligenix Orphan Drug Designation for the Prevention...

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection FDA Grants Soligenix Orphan Drug Designation for the Prevention and...

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection

Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte With the European Medicines Agency Soligenix Announces Agreement on the Design of a Second...

Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte With the European Medicines Agency

Soligenix, Inc. (NASDAQ:SNGX  Free Report)  Investment analysts at Zacks Small Cap upped their FY2024 earnings per share estimates for shares of Soligenix in a research report issued...

Zacks Small Cap Brokers Boost Earnings Estimates for Soligenix, Inc. (NASDAQ:SNGX)

Soligenix GAAP EPS of -$0.79

Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results PR Newswire PRINCETON, N.J., March 15...

Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Soligenix forms Medical Advisory Board for Behcet's Disease

Soligenix Announces Formation of Behet's Disease Medical Advisory Board Soligenix Announces Formation of Behet's Disease Medical Advisory Board PR Newswire PRINCETON, N.J., Feb. 8, 2024 Phase 2a...

Soligenix Announces Formation of Behet's Disease Medical Advisory Board

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Volume	1,360.00
52-Wk High	$4.20
52-Wk Low	$0.3705

SNGX Soligenix Inc

About

Feed

News

Fundamentals